BioTime Subsidiary LifeMap Sciences Announces Publication of Research Report Describing LifeMap Discovery™

  BioTime Subsidiary LifeMap Sciences Announces Publication of Research Report
  Describing LifeMap Discovery™

Business Wire

ALAMEDA, Calif. -- July 18, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today that the LifeMap Discovery™ product has been documented in a
published paper authored by LifeMap Sciences’ research and development team.
LifeMap Discovery™ (available as of November 2012 via
http://discovery.lifemapsc.com/) is the first “roadmap” directing scientists
through the many hundreds of branch points in the stems of the tree of human
cellular life. It also merges experimental knowledge on stem cell biology and
regenerative medicine, striving to aid researchers in the quest to produce
functional cells capable of regenerating particular tissues in the body, for
the treatment of a variety of degenerative diseases.

LifeMap Discovery™ is a key component of LifeMap’s therapeutic discovery
collaboration with BioTime and is utilized in conjunction with LifeMap’s
proprietary bioinformatics tools to select the PureStem™ cells that are most
likely to be useful in developing cell-based regenerative medicine therapies
for a wide range of diseases.

The publication titled “LifeMap Discovery™: The embryonic development, stem
cells, and regenerative medicine research portal” in the open access
peer-reviewed journal PLOS ONE can be viewed via the link
http://dx.plos.org/10.1371/journal.pone.0066629. The publication describes the
scientific and technological foundations of LifeMap Discovery™, the first road
map of embryonic development on a cellular level. Key features that are
described in the publication include the following:

Embryonic development tree

LifeMap Discovery™ displays more than 1,400 cell types and anatomical
structures of the developing embryo and the cellular differentiation that
occurs during mammalian embryonic development, branching from the zygote to
the progenitor cells and terminating at the mature cells. It covers
developmental paths of various types of cells, including blood, endothelium,
motor neurons, bone, cartilage and many more.

Stem cell differentiation protocols

LifeMap Discovery™ provides more than 100 protocols used to induce
differentiation of various embryonic and progenitor cells and of induced
pluripotent stem cells into various cell types (for example, a protocol for
derivation of motor neuron-like cells). Each protocol is displayed in a “card”
that contains an informative and interactive viewer, sketching the protocol in
a stepwise fashion.

Regenerative medicine

LifeMap Discovery™ provides a wealth of information on diseases which
represent potential targets for cell-based therapeutic approaches and
medically relevant information relating to regenerative medicine. It also
provides cell-based therapy approaches that apply cultured stem cells towards
treatment of degenerative diseases, via replacement of damaged cells or
tissues, and/or stimulation of the body's natural repair mechanisms.

Gene expression and signaling

Cells and anatomical compartments of the developing embryo are characterized
by specific gene expression profiles and selective markers, as well as by
signaling molecules that participate in pathways which guide embryonic
development. LifeMap Discovery™ provides this molecular information for
various cell types as well as for cultured stem, progenitor and primary cells.
It also provides a centralized means of identifying cell types throughoutin
vivoembryonic development orin vitrostem cell differentiation procedures,
based on specific gene expression profiles.

“The sophisticated detail in the LifeMap Discovery™ database is a reflection
of a movement underway in regenerative medicine toward a higher definition of
cell types in research and therapy,” said Dr. Michael West, CEO of BioTime.
“We believe the database will not only bring more traffic to the LifeMap
database suite, but will also be the backbone for moving this increasingly
complex field toward clinical application.”

“The publication describing LifeMap Discovery™ in a leading journal in its
field is a validation of the scientific merits of this leading edge
state-of-the-art product,” stated David Warshawsky, Ph.D., President and CEO
of LifeMap Sciences. “Our team is dedicated to continuing to enhance LifeMap
Discovery™ and we are delighted to see the rapid growth of use by the global
research community, already several tens of thousands of users. We are eager
to see the impact that this remarkable resource will have in the
transformative field of regenerative medicine.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
the LifeMap Integrated Biomedical Knowledgebase, the discovery platform for
biomedical and stem cell research. This web-based platform includes
GeneCards^®, the leading human gene compendium; LifeMap Discovery™, the
embryonic development, stem cell research and regenerative medicine
compendium; and MalaCards, the human disease compendium. According to Google
Analytics, the sites have generated more than 2,000,000 unique visitors with
more than 13,000,000 page views, from more than 3,000 universities,
institutions and biomedical companies in the past 12 months.

Via LifeMap BioReagents™, LifeMap offers leading edge reagents to researchers
in academia, research hospitals, and biotech and pharma companies. LifeMap is
BioTime’s principal marketing subsidiary for research products, including
PureStem™ human progenitor cells, PureStem™ packages, clinical and research
grade human embryonic stem cell (hES) lines, culture media, and cell
differentiation kits. The eCommerce portal also offers select recombinant
proteins, including growth factors, signaling molecules, differentiation
factors, cytokines and chemokines that complement BioTimeresearch product
lines.

In therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize the Integrated Biomedical Knowledgebase to aid in the development of
BioTime’s proprietary library of more than 200 PureStem™ human progenitor cell
types into products for the treatment of human diseases, especially
degenerative diseases that might be treatable with cell replacement therapies.
A bioinformatics platform developed by LifeMap is used to select the PureStem™
cells that are most likely to be useful in developing cell-based regenerative
medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com

Contact:

BioTime, Inc.
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com
 
Press spacebar to pause and continue. Press esc to stop.